Comments on: Some Light Reading For Novartis Execs: Damage Control For Dummies http://www.pharmalot.com/2007/03/some_light_reading_for_novarti/ News, Comment and Conversation Fri, 10 Feb 2012 15:45:42 +0000 http://wordpress.org/?v=2.6.2 By: ed http://www.pharmalot.com/2007/03/some_light_reading_for_novarti/#comment-2865 ed Tue, 06 Mar 2007 15:49:51 +0000 http://plt.starledger.webfactional.com/2007/03/some_light_reading_for_novarti/#comment-2865 Hi Dr. Banerji, Thanks for writing. But I'm confused about your last point. Are you saying you feel that Novartis is or isn't entitled to pursue its case? My own view: the company has the right to go to court. It's the proper forum, of course, for disputes. By doing so, however, Novartis can't force India to changes its laws. Although if there were improper influence over this process, that would be a different matter. In any event, please clarify your comment for me. Thanks Ed Hi Dr. Banerji,

Thanks for writing.

But I’m confused about your last point. Are you saying you feel that Novartis is or isn’t entitled to pursue its case?

My own view: the company has the right to go to court. It’s the proper forum, of course, for disputes. By doing so, however, Novartis can’t force India to changes its laws. Although if there were improper influence over this process, that would be a different matter. In any event, please clarify your comment for me.

Thanks
Ed

]]> By: Dr S Banerji http://www.pharmalot.com/2007/03/some_light_reading_for_novarti/#comment-2864 Dr S Banerji Tue, 06 Mar 2007 14:41:40 +0000 http://plt.starledger.webfactional.com/2007/03/some_light_reading_for_novarti/#comment-2864 Poor patients, who used to get Glivec free of cost, regulators who were given new safety information on Glivec by Novartis, more than a decade after molecule discovery, and oncologists who had new options from innovative formulation development, are also losers, apart from Novartis! The company is a valid corporate citizen of sovereign India, and is entitled to seek redress under the national system of justice: foreign entities, regardless of their garbs, have no locus standii to interfere in India's internal affairs. Poor patients, who used to get Glivec free of cost, regulators who were given new safety information on Glivec by Novartis, more than a decade after molecule discovery, and oncologists who had new options from innovative formulation development, are also losers, apart from Novartis! The company is a valid corporate citizen of sovereign India, and is entitled to seek redress under the national system of justice: foreign entities, regardless of their garbs, have no locus standii to interfere in India’s internal affairs.

]]>